Context: Treatment of multidrug resistant tuberculosis (MDR-TB) is challenging. In India, standard treatment regimen is established by Revised National Tuberculosis Control Programme (RNTCP). Adequate follow-up of patients during the treatment period is a challenging task under programmatic conditions. We did a retrospective analysis of patients enrolled and treated under the national programme to study the outcome.
Introduction
Multi drug resistant tuberculosis (defined as resistance to at least Rifampicin and Isoniazid) is a worldwide public health problem. As per recent global tuberculosis report of WHO, 5% of TB cases are estimated to have MDR-TB globally. 3.5% incidence of MDR-TB is reported among new cases. The proportion is higher among previously treated cases, about 20.5%. As per the data provided by national TB programs in 2013, an estimated 300,000 cases of MDR-TB are present. More than half of these cases were in India, China and the Russian federation [1] .
WHO issued a guideline for the management of drug resistant TB in 1996. Programmised management for drug resistant tuberculosis (PMDT) services in India was initiated from August 2007. A standard category IV regimen for MDR-TB treatment has been approved in India. It is implemented under Revised National Tuberculosis Control Programme (RNTCP)-National DOTS plus committee [2] . Globally, only 48% of MDR-TB cases detected in 2011 were successfully treated. 16% died, 24% did not have their treatment documented or treatment interrupted and 12% were not cured despite proper treatment [1] . So, any effort made to determine the treatment outcome helps us to evaluate the programme, its efficacy and identifying the constraints.
Materials and methods
A retrospective cohort study of MDR-TB cases enrolled for treatment in 2011-2012 was done at SDSTRC and Rajiv Gandhi Institute of Chest Diseases (RGICD), a tertiary chest institute in Bangalore, India. Data were obtained from case sheets, registers and treatment cards of patients from August 2011 to August 2014.
Study population -All MDR-TB cases confirmed by RNTCP accredited laboratory and initiated with therapy from August 2011 to June 2012 as per PMDT guidelines. Patients belonged to various districts of Karnataka state.
All patients were hospitalised for pre-treatment investigations and treatment initiation. Patients were started on standardised Cat-IV regimen which includes Kanamycin, Levofloxacin, Ethionamide, Pyrazinamide, Ethambutol, Cycloseriene for 6-9 months and Levofloxacin, Ethionamide, Ethambutol and Cycloseriene for 18 months. PAS was used as a substitute drug in the case of major adverse effect or initial resistance to any of the second line drugs. Patients were monitored for tolerance and adverse drug reactions. After 10-30 days of hospitalisation, patients continued community based treatment at peripheral centres. Follow up sputum smears and culture were done as per guidelines. For follow up examination the sputum specimens were collected and examined by smear and culture at least 30 days apart from the 3rd to 7th month of treatment (i.e. at the end of the months 3, 4, 5, 6 and 7) and at 3-monthly intervals from the 9th month onward till the completion of treatment (i.e. at the end of the months 9, 12, 15, 18, 21 and 24). Patients will be considered culture converted after having two consecutive negative cultures taken at least one month apart. Time to culture conversion is calculated as the interval between the date of MDR-TB treatment initiation and the date of the first of these two negative consecutive cultures. Patients were referred to RGICD for management of any adverse drug reactions and for declaration of treatment outcome. Data were compiled and analysed for various demographic, clinicoradiological profile and treatment outcome.
Outcome definitions:
Cure: A patient who has completed treatment and has been consistently culture negative (with at least 5 consecutive negative results in the last 12-15 months). If one followup positive culture is reported during the last three quarters, patient will still be considered cured provided this positive culture is followed by at least 3 consecutive negative cultures, taken at least 30 days apart, provided that there is clinical evidence of improvement.
Treatment completed: A patient who has completed treatment according to guidelines but does not meet the definition for cure or treatment failure due to lack of bacteriological results. Treatment failure: Treatment will be considered to have failed if two or more of the five cultures recorded in the final 12-15 months are positive, or if any of the final three cultures are positive. Death: A patient who dies for any reason during the course of MDR-TB treatment.
Treatment default: A patient whose treatment was interrupted for two or more consecutive months for any reasons.
Transfer out: A patient who has been transferred to another reporting unit (DR-TB Centre in this case) and for whom the treatment outcome is not known. Till the time the PMDT services are available across the country, the MDR-TB patients can be transferred out only to those districts, within or outside the state, where these services are available. If a patient moves from one district to another, both of which are covered by the same DR-TB Centre, transfer out will not be required.
Results
The study included 69 proved MDR-TB patients enrolled for treatment. Demographic, clinico-radiological and resistance profile of patients are described in Table 1 .
Of the 69 patients 46 were male (66.7%) and 23 were females (33.3%). Mean age of the patients was 35.8 years (11-65 years) and mean body weight was 46.5 kg (19-72 kgs). Both urban and rural populations were affected almost equally. 12 patients (17.4%) were alcoholic. 55 patients were re-treatment (Cat-II) failure and 14 patients (20.3%) were Cat-I failure. 3 patients had a history of treatment with 2 or more second line drugs for more than one month. 72.5% had radiological evidence of extensive disease (defined as presence of cavities and/or moderately dense infiltrates involving more than one lobe); 63.8% had bilateral disease and 19.3% had cavitary disease. 37 patients (53.6%) had initial sputum smear grade 1+/less and only 27.5% had 3+ grade. Resistance pattern to first line drugs varied. 25 patients (36.2%) were resistant to SHRE, 20 patients (29%) were HRS resistant. 11 patients (16%) were resistant to HRE and 13 patients (18.8%) were HR resistant. Concomitant medical disease was present in 20 (29%) cases. 8 (11.6%) were diabetic and 3 (4.4%) were HIV positive. All HIV positive cases were already on anti-retroviral treatment.
Of the total 69 patients 49 strictly adhered to treatment but 20 (29%) were irregular. 13 patients had not completed treatment of even 3 months and so follow up sputum results were available for 56 patients. Among these 56 patients, 48 (82.14%) had sputum culture conversion between 3 and 12 months. Culture conversion rate was 33.9% (19/56) and 62.5% (35/56) at 3 months and 6 months respectively (Fig. 2) .
At the end of the treatment period, 33 patients (47.8%) were declared cured, 19 died (27.5%), 10 defaulted (14.5%), 5 were failures (7.3%) and 2 transferred out ( Fig. 1 ). Of the 33 cured patients, 14 (42.4%) had sputum conversion by 3 months and 26 (78.8%) by 6 months. Only 7 converted between 6 and 12 months of treatment.
Failures
Out of 5 cases declared as failures, 2 had a history of second line drugs for 6-12 months prior to starting of Cat-IV treatment. 2 cases were confirmed to be XDR-TB (Kanamycin and Ofloxacin resistant). 1 had only Ofloxacin resistance.
Expired cases
Out of 19 patients who died during the treatment period only 3 were females. 16 cases had extensive disease on chest X-ray. 10 patients died before 3 months of treatment and no follow up culture was available. 5 (26.3%) patients had sputum conversion before death. 6 patients were not adherent to treatment. 6 patients died due to non TB causes like hepatic encephalopathy secondary to cirrhosis, corpulmonale, malignancy. 1 was HIV positive and 1 was diabetic. 3 patients committed suicide; 1 within 2 months and 2 after 10-14 months of treatment. 2 had major adverse reactions like hepatotoxicity and hypothyroidism.
Default cases
Out of the 10 defaulters, 8 were males, 5 alcoholics. 6 patients completed 12 months of treatment and 5 (50%) had sputum conversion prior to default. 6 (60%) patients cited adverse drug reaction as the cause of default (5-severe Gastritis and intolerance, 1-Ototoxicity) 2 had associated diabetes mellitus and 1 was migratory.
Adverse drug reactions ( Table 2) 60.9% of 69 MDR-TB patients had adverse drug reactions of varying severity. 32 (46.4%) had minor reactions, requiring no/ temporary modification of treatment regimen. Most common (21.7%) were related to gastrointestinal systems like nausea, vomiting and abdominal discomfort. 10 (14.5%) patients complained of severe adverse reaction requiring treatment modification. These included severe arthralgia (2 patients), otovestibular toxicity (3) nephrotoxicity (1) mental disturbances (3) and hypothyroidism (1) (see Table 2 ).
Discussion
Our study involved outcome analysis of MDR-TB patients managed with standardised a treatment regimen of 24 months under programmatic conditions of RNTCP.
Sputum culture conversion is the first indicator of the response to treatment and early conversion is definitely desirable. In our study 82.14% achieved sputum culture conversion between 3 and 12 months. Culture conversion rate at 3 months was only 33.9% in contrast to 82% reported from TRC Chennai [3] and LRS Delhi [4] , 57% at the Ahmedabad centre [5] . At the time this cohort of patients was under treatment, there was only one reference laboratory catering to entire state MDR-TB patients. Delay in sending follow up samples, contamination being reported in culture reports can be a reason to some extent. Default rate (14.5%) was low as observed in studies done in Chennai [3] (13.16%), Egypt [6] (14%) and Bangladesh [7] (12%) as compared to few other studies [4, 5, 8] reporting a high default rate of 18-24%. Alcohol consumption, migration and adverse drug reactions were found to be main causes for default in our study.
Our study had a failure rate of 7.3%, similar to studies from Delhi [4] , Bangladesh [7] and Egypt [6] . But studies done in Ahmedabad [5] and Chennai [3] reported a failure rate of 13-13.2% respectively.
A systematic review and meta-analysis of treatment outcome of MDR-TB reported a cure rate of 62% [9] . A good cure rate was also reported from other studies within and outside India using standardised treatment regimen [3, 4, 6, 7] . However in our study we observed a cure rate of 47.8% only, which is comparable to a low cure rate observed in a recent studies in Ahmedabad [5] which reported a 39.13% cure rate and also 48% from a study in Peru [10] .
Relatively poor cure rate in our study was observed mainly due to the high death rate (27.5%). 6 (31.6%) patients who died had non TB causes like major co morbidities. However outcome was equally good (62.5% cure rate) in MDR-TB patients associated with diabetes mellitus. So, diabetes mellitus was not influencing treatment outcome. 10 patients died even before completing 3 months of treatment. Delay in diagnosing and initiating treatment could be a cause. Extensive disease and severe adverse drug reactions were seen in others. Unfortunately 3 (15.8%) patients committed suicide during treatment. Though social and family problems were quoted, disease and Cycloseriene induced adjustment disorders, depression and suicidal tendencies cannot be ruled out. Our cohort contained MDR-TB patients from all districts of Karnataka, who continued treatment from peripheral facilities after treatment initiation at our institute. Clinical monitoring through monthly follow up, as desirable was a non complaint by the patients. So major adverse reactions could have been ignored/missed at peripheral health facilities.
Only 36 patients (52.2%) completed 24-27 months of treatment. Considering this 91.66% of those who completed the treatment were declared cured. Even, 26% of patients who died and 50% of defaulters had sputum conversion prior to the incident. This indicates the good efficacy of the standard treatment regimen. But, the major challenge is to keep patients adhered to treatment and preventing default. Adequate follow up, early identification and management of adverse drug reactions are the key to favourable treatment outcome. Providing good laboratory backup is a good aid for follow up. Major behavioural disturbance and mental illness were caused possibly due to Cycloseriene; delay in identifying the same under programmatic conditions leading to casualty draws attention. A prospective study on the same is needed so as to think about substituting Cycloseriene with PAS in the regimen.
Conclusion
Treatment of MDR-TB is definitely challenging. Standardised treatment regimen is effective enough. Various treatment factors (long duration, adverse drug reactions) patient factors (migration, extensive disease, non adherence, co morbidities) and programmatic factors (lack of manpower, inadequate laboratory facilities) are a major hindrance to the success. Although many adverse drug reactions are reported, only few of them are a limiting factor for treatment. Early diagnosis of MDR-TB, strict follow-up of patients, adequate management of other co morbidities, identifying major adverse drug reactions and their early effective management increases the cure rate.
